Tech Company Financing Transactions
Elucid Funding Round
Elucid closed a $27 million Series B funding round on 6/23/2022. Investors included Biovision Ventures, BlueStone Venture Partners and Bold Brain Ventures.
Transaction Overview
Company Name
Announced On
6/23/2022
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate growth and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
2 Park Plaza
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Blake Richards
President
Andrew Buckler
Vice President
Nasibeh Vatankhah
VP - Bus. Development
Jason Bottiglieri
VP - Engineering
Murali Ayyapillai
Browse more venture capital transactions:
Prev: 6/23/2022: Tapcheck venture capital transaction
Next: 6/23/2022: Modern Synthesis venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs